Sanofi's Wayrilz Receives Orphan Drug Designation for IgG4-Related Disease in Japan

Sanofi’s Waylirz Receives Orphan Drug Status in Japan

Sanofi has announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has designated Waylirz (rilzabrutinib) as an orphan drug for the treatment of IgG4-related disease (IgG4-RD). Currently, Waylirz is not approved for this use in any country.

Significance of Orphan Drug Designation for Sanofi

The MHLW grants orphan drug status to treatments targeting rare conditions that affect fewer than 50,000 individuals in Japan. This designation is intended to stimulate the development of therapies for rare diseases by offering benefits such as expedited consultations, tax incentives, financial support, and accelerated review processes.

For Sanofi, this recognition brings both regulatory and financial support as Waylirz progresses through clinical trials for IgG4-RD—a rare disorder that can impact multiple organs and may cause lasting organ damage if untreated. The orphan status is expected to speed up development and ease some of the challenges associated with bringing the drug to market, helping Sanofi address a significant medical need.

This is the third time rilzabrutinib has received orphan drug designation for IgG4-RD, following similar approvals in the United States and the European Union.

Overview of Waylirz

Waylirz is a next-generation BTK inhibitor developed to treat a range of rare immune and inflammatory disorders by modulating multiple immune pathways. It is already approved for immune thrombocytopenia (ITP) in both the United States and the European Union, and a regulatory submission for this indication is under review in Japan.

The orphan drug status for IgG4-RD in Japan was supported by encouraging results from a phase 2 clinical trial, which demonstrated that 52 weeks of treatment with Waylirz led to fewer disease flare-ups, improved disease markers, and reduced reliance on glucocorticoids.

Sanofi is currently conducting advanced-stage trials of Waylirz for IgG4-RD, sickle cell disease (SCD), and warm autoimmune hemolytic anemia (wAIHA). Additionally, the drug is being tested in mid-stage studies for asthma and chronic spontaneous urticaria (CSU).

Competitive Landscape for Waylirz

Waylirz faces competition in several of its intended treatment areas, with the level of competition varying by disease and stage of development.

• For ITP, Waylirz competes with Amgen’s Nplate and Rigel Pharmaceuticals’ Tavalisse. Although these rivals use different mechanisms of action, they represent significant competition for Waylirz, which is newer to the market.
• If approved for IgG4-RD, Waylirz may contend with existing therapies such as Amgen’s Uplizna.
• In the CSU space, Waylirz would be up against Dupixent—a leading therapy co-marketed by Sanofi and Regeneron, which already holds a strong position in the immunology market.